CN113243532A - Natural gel of dietary supplement capable of improving irritable bowel syndrome and preparation method thereof - Google Patents
Natural gel of dietary supplement capable of improving irritable bowel syndrome and preparation method thereof Download PDFInfo
- Publication number
- CN113243532A CN113243532A CN202110646893.7A CN202110646893A CN113243532A CN 113243532 A CN113243532 A CN 113243532A CN 202110646893 A CN202110646893 A CN 202110646893A CN 113243532 A CN113243532 A CN 113243532A
- Authority
- CN
- China
- Prior art keywords
- parts
- gamma
- poly
- glutamic acid
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002551 irritable bowel syndrome Diseases 0.000 title claims abstract description 27
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims abstract description 42
- 235000019477 peppermint oil Nutrition 0.000 claims abstract description 42
- 239000004220 glutamic acid Substances 0.000 claims abstract description 35
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 33
- 239000000499 gel Substances 0.000 claims abstract description 32
- 108010010803 Gelatin Proteins 0.000 claims abstract description 22
- 239000008273 gelatin Substances 0.000 claims abstract description 22
- 229920000159 gelatin Polymers 0.000 claims abstract description 22
- 235000019322 gelatine Nutrition 0.000 claims abstract description 22
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 16
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000811 xylitol Substances 0.000 claims abstract description 16
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 16
- 229960002675 xylitol Drugs 0.000 claims abstract description 16
- 235000010447 xylitol Nutrition 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 239000011259 mixed solution Substances 0.000 claims description 12
- 239000003208 petroleum Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 6
- 238000009210 therapy by ultrasound Methods 0.000 claims description 6
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 5
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 5
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 5
- 239000003431 cross linking reagent Substances 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 5
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 239000007987 MES buffer Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 208000024891 symptom Diseases 0.000 abstract description 5
- 230000029087 digestion Effects 0.000 abstract description 4
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 229960002989 glutamic acid Drugs 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 13
- 206010012735 Diarrhoea Diseases 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 210000000941 bile Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 108700022290 poly(gamma-glutamic acid) Proteins 0.000 description 3
- 229920002643 polyglutamic acid Polymers 0.000 description 3
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010017367 Frequent bowel movements Diseases 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000008845 cholagoga Substances 0.000 description 1
- 229940124571 cholagogue Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000010657 mentha arvensis oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000010346 psychosocial stress Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
- A23L29/281—Proteins, e.g. gelatin or collagen
- A23L29/284—Gelatin; Collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention belongs to the technical field of functional foods, and particularly relates to a dietary supplement natural gel for improving irritable bowel syndrome and a preparation method thereof. The feed is prepared from the following raw materials in parts by weight: 10-15 parts of poly-gamma-glutamic acid, 15-20 parts of chitosan oligosaccharide, 5-8 parts of peppermint oil, 4-6 parts of gelatin, 4-6 parts of xylitol, 4-6 parts of citric acid and 39-58 parts of water. The dietary supplement provided by the invention has appropriate sweetness, good taste, fresh and cool taste, easy digestion, simple preparation method, safety, harmlessness, low raw material cost, good gelling effect, rapid digestion after use and high bioavailability. The peppermint oil extracted by the invention has high purity, the gel dietary supplement has stronger human body affinity due to the addition of the chitosan oligosaccharide, and the stability of the peppermint oil can be improved and the symptom of irritable bowel syndrome can be relieved by the addition of the poly-gamma-glutamic acid.
Description
Technical Field
The invention belongs to the technical field of functional foods, and particularly relates to a dietary supplement natural gel for improving irritable bowel syndrome and a preparation method thereof.
Background
Irritable Bowel Syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain, abdominal distension with altered bowel habits and a lack of functional disturbances of the gastrointestinal tract structure and biochemical abnormalities. With the improvement of living standard, the incidence of IBS at home and abroad is on the trend of increasing year by year, and the patients are repeatedly examined for a long time, so that not only the living quality is reduced, but also the social medical expenses are increased, and higher social pressure is brought. According to the Roman IV standard, the diagnosis points are that repeated abdominal pain occurs, the average occurrence is at least 1 d/week in nearly 3 months, and the diagnosis is accompanied by 2 or more than 2 items, namely (1) the abdominal pain is related to defecation, (2) the abdominal pain is accompanied by the change of defecation frequency, and (3) the abdominal pain is accompanied by the change of stool characteristics (appearance). According to the Roman IV classification criteria, IBS can be classified into mixed IBS (IBS-M), diarrhea IBS (IBS-D), constipation IBS (IBS-C) and unclassified IBS (IBS-U). The global prevalence rate of IBS is about 11%, the IBS tends to rise year by year, the regional difference is large, the incidence rate of IBS in China is about 4% -9%, and the prevalence rate in European and American countries is as high as 10% -20%. The pathogenesis of IBS is not clear, and the clinical symptoms are complex, so that the IBS cannot be explained by a single pathophysiological mechanism, and at present, various factors such as genetic susceptibility, viscercosis, gastrointestinal motility dysfunction, psychosocial stress, brain-intestinal axis interaction, inflammation, dietary factors, intestinal flora change and the like are considered to play important roles in the occurrence and development of IBS symptoms.
Poly-gamma-glutamic acid (gamma-PGA) is a typical polyelectrolyte, and an amino polymer formed by polymerizing D-glutamic acid and L-glutamic acid through a gamma-glutamine bond has a relative molecular weight of generally 10 to 100 ten thousand. Compared with other polymeric macromolecular compounds, the gamma-PGA can be degraded into glutamic acid monomers in vivo, is necessary for human bodies, has excellent biocompatibility, low immunogenicity and no toxic or side effect, and is incomparable with other materials. The aqueous γ -PGA solution exhibits specific properties in terms of viscosity and the like.
Chitosan Oligosaccharide (CO) is also called Chitosan oligosaccharide and oligomeric Chitosan, and is a low molecular weight product with good water solubility, large functional effect and high biological activity. It has several unique functions of high solubility, complete water solubility, easy absorption and utilization by organism, etc. and its action is 14 times that of chitosan. CO is the only cationic basic amino-oligosaccharide with positive charge in nature and is animal cellulose. The research proves that: CO has the functions of improving immunity, inhibiting tumor cell growth, promoting liver and spleen antibody formation, promoting calcium and mineral substance absorption, proliferating beneficial flora of human bodies such as bifidobacterium, lactobacillus and the like, reducing blood fat, blood pressure and blood sugar, regulating cholesterol, losing weight, preventing adult diseases and the like, and can be applied to the fields of medicines, functional foods and the like. The chitosan oligosaccharide has water solubility, is convenient to use, has obvious performance effect of inhibiting putrefying bacteria, and has multiple functions.
The main components of oleum Menthae Dementholatum [ Mentha arvensis oil ] include menthol, menthone, etc. At present, the traditional Chinese medicine composition is widely applied to treatment of digestive system diseases, particularly treatment of liver and gall system diseases, and has the effects of relieving spasm, stopping vomiting and benefiting gallbladder, increasing the discharge amount of bile acid in bile, changing the pH value of the bile and the like. Animal experiments show that after the danshu capsule (the main component is peppermint oil) is administrated to duodenum of a rat, the secretion of bile of the rat is obviously increased, the effect has certain dose correlation, and compared with that before the danshu capsule is administrated, the content of bile acid in the bile is increased and the content of cholesterol is reduced, which shows that the peppermint oil can promote the discharge of the bile acid in the bile and has obvious cholagogue effect. Clinical research further discovers that the Danshu capsule has better functions of dissolving and removing urinary calculus, can obviously reduce the level of serum alanine Aminotransferase (ALT) and obviously improve liver function, and has no adverse reaction after long-term application. Peppermint oil has a relatively positive effect on IBS and is currently approved by the United kingdom as a first-line drug for the treatment of IBS. The oleum Menthae Dementholatum is volatile oil extracted from herba Menthae, and the effective components in oleum Menthae Dementholatum can not exert their medicinal value sufficiently due to volatilization of oleum Menthae Dementholatum in the process of storage, thereby limiting direct use of oleum Menthae Dementholatum.
Disclosure of Invention
The invention aims to solve the problems, and provides a novel dietary supplement natural gel for improving irritable bowel syndrome, which has high peppermint oil loading efficiency, good biocompatibility and good taste, so that the symptoms of the irritable bowel syndrome can be improved.
The invention also provides a preparation method of the natural gel of the dietary supplement.
In order to achieve the purpose, the invention relates to the following specific technical scheme:
the invention provides a dietary supplement natural gel for improving irritable bowel syndrome, which is prepared from the following raw materials in parts by weight: 10-15 parts of poly-gamma-glutamic acid, 15-20 parts of chitosan oligosaccharide, 5-8 parts of peppermint oil, 4-6 parts of gelatin, 4-6 parts of xylitol, 4-6 parts of citric acid and 39-58 parts of water.
The extraction method of the peppermint oil used by the invention comprises the following steps:
(1) cleaning newly collected herba Menthae, draining, deactivating enzyme, drying in the sun, and pulverizing into powder;
(2) extracting herba Menthae powder with mixed solvent of petroleum ether and isopropyl palmitate for 3 times, and subjecting the extractive solution to ultrasonic treatment to obtain supernatant to obtain extractive solution; mixing extractive solutions, and evaporating petroleum ether in the filtrate with rotary evaporator to obtain oleum Menthae Dementholatum;
(4) dehydrated with anhydrous sodium sulfate and filtered through filter paper.
Further, in the step (1), the water-removing is carried out for 10min at 112 ℃; .
Further, in the step (2), the material-liquid ratio of the mint powder to the mixed solvent is 1 g: 10 mL; the time of each leaching is 4 hours; the volume ratio of the petroleum ether to the isopropyl hexadecanoate is 1: 0.2.
the invention also provides a preparation method of the natural gel of the dietary supplement, which comprises the following steps:
(1) dissolving poly-gamma-glutamic acid in parts by weight in deionized water, adjusting the pH value by using MES buffer solution, adding a cross-linking agent, performing ultrasonic activation, and placing on a shaking table for reaction for 15min to obtain poly-gamma-glutamic acid solution;
(2) slowly adding the poly gamma-glutamic acid solution into the chitosan oligosaccharide solution at room temperature while stirring to obtain a mixed solution;
(3) weighing gelatin powder with a certain weight, uniformly stirring, heating to fully dissolve, then adding xylitol and citric acid, fully stirring, and uniformly mixing to obtain a mixed solution;
(4) dripping peppermint oil into the mixed solution obtained in the step (2), and uniformly stirring to obtain a poly gamma-glutamic acid/chitosan oligosaccharide/peppermint oil solution;
(5) mixing the poly-gamma-glutamic acid/chitosan oligosaccharide/peppermint oil solution with the mixed solution, adding water, fully and uniformly stirring, and placing in a refrigerator to be cooled into gel.
Further, in the step (1), the crosslinking agent is EDC and NHS; the mass ratio of the poly gamma-glutamic acid to the NHS is 1: 6; the mass ratio of EDC to NHS is 8: 5.
further, in the step (2), the concentration of the poly gamma-glutamic acid solution is 2 g/L; the molecular weight of the chitosan oligosaccharide is 1000Da, and the concentration of the chitosan oligosaccharide solution is 1 g/ml.
Further, in the step (3), the gelatin freezing force (g) of the gelatin is 100; the mass ratio of the xylitol and the citric acid to the gelatin is 1:1: 1.
The poly-gamma-glutamic acid used by the invention is obtained by fermenting and extracting bacillus licheniformis (bacillus licheniformis), and the fermentation and extraction method comprises the following steps:
1) weighing a basic culture medium, dissolving to obtain a basic culture medium solution, weighing each component of an optimized culture medium, adding into the basic culture medium solution, fixing the volume, and adjusting the pH value to 7.5 by solid NaOH;
2) subpackaging the culture medium into conical flasks (50 ml/flask), sterilizing at 150 deg.C with 100-;
3) centrifuging the fermentation liquor, adding 2-7 times volume of ethanol into supernatant to precipitate for 10-24h, centrifuging, precipitating the obtained supernatant with 2-6 times volume of ethanol, centrifuging, and rotary evaporating to obtain residual solid;
4) dissolving a constant weight sample in distilled water, and dialyzing and purifying to obtain a purified sample;
5) and dissolving the purified sample in distilled water, and spray drying to obtain poly gamma-glutamic acid powder.
The basic culture medium used by the invention comprises the following components (g/L): 10g of glucose, 13.5g of citric acid, 23g of L-glutamic acid and NH4Cl 6.8 g，K2HPO4· 3H2O 0.8 g，MgSO4· 7H2O 0.5g，FeCl3·6H2O 0.05 g，CaCl2·2H2O 0.17 g，(NH4)2Mo7O40.26g, pH7.5. The optimized culture medium used by the invention comprises the following components (g/L): 10-15 parts of NaCl, 1.0-2.5 parts of alpha-ketoglutaric acid, 0.02-0.1 part of Mn (II), 0.2-1.0 part of L-glutamine and 5-15 parts of glycerol.
The invention has the advantages that
1. The poly-gamma-glutamic acid and the chitosan oligosaccharide used in the invention are colorless, nontoxic, tasteless and easily degradable microbial fermentation extracts, the carboxyl of gamma-PGA and the amino of CO have high coordination coefficient and stable structure, and the load of the peppermint oil is increased.
2. The dietary supplement provided by the invention has appropriate sweetness, good taste, fresh and cool taste, easy digestion, simple preparation method, safety, harmlessness and low raw material cost.
4. In the preparation process, the prepared replenisher has the advantages of uniform raw materials, good gelling effect, rapid digestion and high bioavailability after use.
5. The peppermint oil extracted by the invention has high purity, the gel dietary supplement has stronger human body affinity due to the addition of the chitosan oligosaccharide, and the stability of the peppermint oil can be improved and the symptom of irritable bowel syndrome can be relieved by the addition of the poly-gamma-glutamic acid.
Detailed Description
The present invention will be described in further detail with reference to specific embodiments, but it should not be construed that the scope of the present invention is limited to the following examples. Various substitutions and alterations can be made by those skilled in the art and by conventional means without departing from the spirit of the method of the invention described above.
Example 1
A peppermint oil gel dietary supplement comprises the following formula: 10 parts of poly-gamma-glutamic acid, 15 parts of chitosan oligosaccharide, 5 parts of peppermint oil, 4 parts of gelatin, 4 parts of xylitol, 4 parts of citric acid and 58 parts of water.
The extraction method of the peppermint oil comprises the following steps:
(1) cleaning newly collected herba Menthae, draining, deactivating enzyme at 112 deg.C for 10min, sun drying, and pulverizing into powder;
(2) extracting herba Menthae powder 20.00g with 600ml petroleum ether and isopropyl hexadecanoate (V: V =1: 0.2) in conical flask for 3 times (200 ml each time), and soaking for 6 hr;
(3) subjecting the leaching solution to ultrasonic treatment for 30min, standing, collecting supernatant, mixing, and evaporating petroleum ether in the filtrate with rotary evaporator to obtain relatively pure oleum Menthae Dementholatum;
(4) dehydrated with anhydrous sodium sulfate and filtered through filter paper.
The preparation method comprises the following steps:
1) dissolving a certain amount of poly-gamma-glutamic acid in deionized water, adjusting pH to 5-6 with MES buffer solution, adding crosslinking agents EDC and NHS, performing ultrasonic treatment for 10min, activating, and placing on a shaker for reaction at 37 ℃ for 15 min.
2) Slowly adding poly-gamma-glutamic acid solution into the chitosan oligosaccharide solution at room temperature, wherein the concentration of poly-gamma-glutamic acid is 2g/L, the molecular weight of the chitosan oligosaccharide is 1000Da, the concentration of the chitosan oligosaccharide is 1g/ml, all solvents are deionized water, stirring at room temperature (600 r/min), carrying out ultrasonic treatment for 10min while stirring, and dialyzing for 1-3h to remove unbound micromolecules.
3) Weighing edible gelatin powder with gelatin freezing force (g) of 100, stirring uniformly, heating to 60 ℃ to fully dissolve gelatin, then adding xylitol and citric acid, stirring fully, and mixing uniformly;
4) dripping peppermint oil into the mixed solution obtained in the step 2), and uniformly stirring;
5) dropwise adding the mixed solution in the step 3) into the mixed solution in the step 4), adding water, and fully and uniformly stirring (800 r/min);
6) cooling the mixed solution obtained in the step 5) into gel in a refrigerator at 4 ℃.
Example 2
A peppermint oil gel dietary supplement comprises the following formula: 10 parts of poly-gamma-glutamic acid, 20 parts of chitosan oligosaccharide, 5 parts of peppermint oil, 4 parts of gelatin, 4 parts of xylitol, 4 parts of citric acid and 53 parts of water.
The preparation method is the same as example 1.
Example 3
A peppermint oil gel dietary supplement comprises the following formula: 15 parts of poly-gamma-glutamic acid, 15 parts of chitosan oligosaccharide, 8 parts of peppermint oil, 4 parts of gelatin, 4 parts of xylitol, 4 parts of citric acid and 50 parts of water.
The preparation method is the same as example 1.
Example 4
A peppermint oil gel dietary supplement comprises the following formula: 15 parts of poly-gamma-glutamic acid, 20 parts of chitosan oligosaccharide, 8 parts of peppermint oil, 6 parts of gelatin, 6 parts of xylitol, 6 parts of citric acid and 39 parts of water.
The preparation method is the same as example 1.
Example 5
A peppermint oil gel dietary supplement comprises the following formula: 12 parts of poly-gamma-glutamic acid, 18 parts of chitosan oligosaccharide, 6 parts of peppermint oil, 5 parts of gelatin, 5 parts of xylitol, 5 parts of citric acid and 49 parts of water.
The preparation method is the same as example 1.
Example 6
A peppermint oil gel dietary supplement is formulated as in example 5.
The extraction method of the peppermint oil comprises the following steps:
(1) cleaning newly collected herba Menthae, draining, deactivating enzyme at 112 deg.C for 10min, sun drying, and pulverizing into powder;
(2) extracting herba Menthae powder 20.00g with 600ml petroleum ether in conical flask, using 200ml each time for 3 times, soaking for 6 hr each time;
(3) subjecting the leaching solution to ultrasonic treatment for 30min, standing, collecting supernatant, mixing, and evaporating petroleum ether in the filtrate with rotary evaporator to obtain relatively pure oleum Menthae Dementholatum;
(4) dehydrated with anhydrous sodium sulfate and filtered through filter paper.
By comparison with the extraction method of peppermint oil in example 1, the yield of peppermint oil was 1.17% when only petroleum ether was used for extraction, whereas the yield of peppermint oil was 1.89% in example 1.
Comparative example 1
A peppermint oil gel dietary supplement is composed of the following raw materials in parts by weight: 12 parts of poly-gamma-glutamic acid, 18 parts of chitosan oligosaccharide, 6 parts of peppermint oil, 5 parts of gelatin, 5 parts of xylitol and 54 parts of water.
The specific preparation method is the same as that of example 1; except that no citric acid was added.
Comparative example 2
A peppermint oil gel dietary supplement is composed of the following raw materials in parts by weight: 18 parts of chitosan oligosaccharide, 6 parts of peppermint oil, 5 parts of gelatin, 5 parts of xylitol, 5 parts of citric acid and 61 parts of water.
The specific preparation method is the same as that of example 1; except that poly-gamma-glutamic acid was not added.
Effects of the embodiment
Comparing the texture properties of example 5 with those of comparative examples 1 and 2, it was found that the elasticity of the gels of comparative example 1 and comparative example 2 was relatively low and the tackiness of the gels was relatively poor compared to example 5. Comparative example 1 is more effective than comparative example 2, probably due to the poor gelling effect caused by the absence of poly-gamma-glutamic acid; meanwhile, when the mass of the citric acid, the xylitol and the gelatin is 1:1: at 1.5, the elasticity and tackiness of the gel prepared were also inferior to those of the examples.
(II) mouse antidiarrheal experiment
Test subjects: the weight of the Kunming mouse is 18-22g, and the Kunming mouse has 50 mice with half male and half female.
The molding method comprises the following steps: after the mice are pre-bred for one week, 10 mice are randomly selected as a blank control group, the physiological saline for gastric lavage is 10mL/kg (solution weight/mouse weight), the equivalent amount of the rhubarb cold immersion liquid of 1g/mL is 0.4mL for the other groups, the gavage is continuously performed once a day for 5 days, the molding condition of the mice is observed on the 6 th day, the weight of the mice is weighed, and the mice with unsuccessful molding are removed (molding success standard: hair is not glossy, feed intake is reduced, mice are compressed, activity is less, reaction is slower, action is slower, and the buttocks have obvious stains).
The test method comprises the following steps: 30 mice were selected from the successfully molded mice and randomly divided into 5 groups of 6 mice, one of which was used as a model control group and fed with placebo, two of which was fed with the same amount of montmorillonite powder as a positive control group, three of which were mint oil gels prepared in example 3, four of which were mint oil gels prepared in example 5, and five of which were mint oil gels prepared in example 1.
Observation indexes are as follows: (ii) stool dilution ratio (ratio of stool number excreted per mouse to total stool number) of mice-stool dilution stage: indicating the degree of defecation of the mice. The size of the area stained by the contaminated filter paper is graded by the dilution. The number of stages is 4 stages, and the standard is as follows: fecal stain diameter < 1cm is grade 1, 1-1.9cm is grade 2, 2-3cm is grade 3, and > 3cm is grade 4. During statistics, the number of the shit stages at each position is counted one by one, then all the shit stages of the mouse are added, and the number of the shit stages is divided by the number of the shit stages to obtain the average number of the shit stages, which is called the shit stage for short. ③ diarrhea index: the product of the rare-feces rate and the rare-feces level. The total number of stools, the number of loose stools and the degree of loose stools were observed for 5h, and the diarrhea index was calculated by multiplying the rate of loose stools by the degree of loose stools.
TABLE 1
And (4) analyzing results:
after administration, diarrhea appeared in each group, which was marked by significantly increased stool frequency, loose stool texture, and mucus appeared in the stools of individual mice. The diarrhea rate and the diarrhea index of the two groups are reduced compared with the three, four and five groups and the one group, namely the experiment group which is fed with the peppermint oil gel has a more obvious effect on the diarrhea of mice, and the treatment of irritable bowel syndrome can be effectively realized.
Claims (8)
1. A dietary supplement natural gel for improving irritable bowel syndrome is characterized by being prepared from the following raw materials in parts by weight: 10-15 parts of poly-gamma-glutamic acid, 15-20 parts of chitosan oligosaccharide, 5-8 parts of peppermint oil, 4-6 parts of gelatin, 4-6 parts of xylitol, 4-6 parts of citric acid and 39-58 parts of water.
2. A dietary supplement natural gel according to claim 1, wherein said peppermint oil is extracted by the method of:
(1) cleaning newly collected herba Menthae, draining, deactivating enzyme, drying in the sun, and pulverizing into powder;
(2) extracting herba Menthae powder with mixed solvent of petroleum ether and isopropyl palmitate for 3 times, and subjecting the extractive solution to ultrasonic treatment to obtain supernatant to obtain extractive solution; mixing extractive solutions, and evaporating petroleum ether in the filtrate with rotary evaporator to obtain oleum Menthae Dementholatum;
(4) dehydrated with anhydrous sodium sulfate and filtered through filter paper.
3. A dietary supplement natural gel according to claim 2, wherein in step (1) said de-enzyming is de-enzyming at 112 ℃ for 10 min.
4. A dietary supplement natural gel according to claim 2 or 3, wherein in step (2), the mint powder and the mixed solvent have a feed-liquid ratio of 1 g: 10 mL; the time of each leaching is 4 hours; the volume ratio of the petroleum ether to the isopropyl hexadecanoate is 1: 0.2.
5. a process for the preparation of a natural gel of dietary supplement as claimed in any one of claims 1 to 4, comprising the steps of:
(1) dissolving poly-gamma-glutamic acid in parts by weight in deionized water, adjusting the pH value by using MES buffer solution, adding a cross-linking agent, performing ultrasonic activation, and placing on a shaking table for reaction for 15min to obtain poly-gamma-glutamic acid solution;
(2) slowly adding the poly gamma-glutamic acid solution into the chitosan oligosaccharide solution at room temperature while stirring to obtain a mixed solution;
(3) weighing gelatin powder with a certain weight, uniformly stirring, heating to fully dissolve, then adding xylitol and citric acid, fully stirring, and uniformly mixing to obtain a mixed solution;
(4) dripping peppermint oil into the mixed solution obtained in the step (2), and uniformly stirring to obtain a poly gamma-glutamic acid/chitosan oligosaccharide/peppermint oil solution;
(5) mixing the poly-gamma-glutamic acid/chitosan oligosaccharide/peppermint oil solution with the mixed solution, adding water, fully and uniformly stirring, and placing in a refrigerator to be cooled into gel.
6. The method according to claim 5, wherein in the step (1), the crosslinking agent is EDC and NHS; the mass ratio of the poly gamma-glutamic acid to the NHS is 1: 6; the mass ratio of EDC to NHS is 8: 5.
7. the method according to claim 5, wherein in the step (2), the concentration of the poly-gamma-glutamic acid solution is 2 g/L; the molecular weight of the chitosan oligosaccharide is 1000Da, and the concentration of the chitosan oligosaccharide solution is 1 g/ml.
8. The process according to claim 5, wherein in the step (3), the gelatin has a gelatin freezing force (g) of 100; the mass ratio of the xylitol and the citric acid to the gelatin is 1:1: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110646893.7A CN113243532A (en) | 2021-06-10 | 2021-06-10 | Natural gel of dietary supplement capable of improving irritable bowel syndrome and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110646893.7A CN113243532A (en) | 2021-06-10 | 2021-06-10 | Natural gel of dietary supplement capable of improving irritable bowel syndrome and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113243532A true CN113243532A (en) | 2021-08-13 |
Family
ID=77187471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110646893.7A Pending CN113243532A (en) | 2021-06-10 | 2021-06-10 | Natural gel of dietary supplement capable of improving irritable bowel syndrome and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113243532A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117481345A (en) * | 2024-01-03 | 2024-02-02 | 四川如源科技有限公司 | Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2006011A (en) * | 1977-08-04 | 1979-05-02 | Rhodes J | Carminative preparations |
| US8187570B1 (en) * | 2005-01-04 | 2012-05-29 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| CN102977594A (en) * | 2012-12-13 | 2013-03-20 | 上海应用技术学院 | Gamma-polyglutamic acid/gelatin nanocapsules and preparation method thereof |
| CN104606680A (en) * | 2014-12-29 | 2015-05-13 | 天津北洋百川生物技术有限公司 | Preparation method of drug-loaded gamma-polyglutamic acid hydrogel |
| CN108553424A (en) * | 2018-05-22 | 2018-09-21 | 江南大学 | A kind of preparation method and products thereof of oral amoxicillin pH response type nano carriers |
-
2021
- 2021-06-10 CN CN202110646893.7A patent/CN113243532A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2006011A (en) * | 1977-08-04 | 1979-05-02 | Rhodes J | Carminative preparations |
| US8187570B1 (en) * | 2005-01-04 | 2012-05-29 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| CN102977594A (en) * | 2012-12-13 | 2013-03-20 | 上海应用技术学院 | Gamma-polyglutamic acid/gelatin nanocapsules and preparation method thereof |
| CN104606680A (en) * | 2014-12-29 | 2015-05-13 | 天津北洋百川生物技术有限公司 | Preparation method of drug-loaded gamma-polyglutamic acid hydrogel |
| CN108553424A (en) * | 2018-05-22 | 2018-09-21 | 江南大学 | A kind of preparation method and products thereof of oral amoxicillin pH response type nano carriers |
Non-Patent Citations (3)
| Title |
|---|
| 兰太富等: "《家庭医保用药知识》", 31 January 2003, 四川科学技术出版社 * |
| 刘福昌等: "《天然药物化学》", 28 February 2013, 华中科技大学出版社 * |
| 梁鑫鑫: "一种新型水凝胶的制备、表征与应用研究", 《中国优秀硕士学位论文全文数据库（电子期刊）工程科技Ⅰ辑》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117481345A (en) * | 2024-01-03 | 2024-02-02 | 四川如源科技有限公司 | Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar |
| CN117481345B (en) * | 2024-01-03 | 2024-04-05 | 四川如源科技有限公司 | Chitosan oligosaccharide composition with gastrointestinal regulating function and functional sugar |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114874344A (en) | Preparation method and application of alkali-extracted polysaccharide of highland barley tender leaves | |
| CN113243532A (en) | Natural gel of dietary supplement capable of improving irritable bowel syndrome and preparation method thereof | |
| CN104367987A (en) | Astragalus mongholicus formulation for veterinary use and preparation method thereof | |
| CN116570640B (en) | Application of sunflower disc alkaloid and derivative in uric acid-reducing and tophus-dissolving product | |
| CN105687036A (en) | Rhizoma bletillae skin care product and method for preparing same | |
| CN106819973B (en) | Preparation method of mulberry microorganism compound preparation with functions of reducing blood sugar and relaxing bowels | |
| CN115010823B (en) | Plantain seed polysaccharide for regulating intestinal flora and preparation method and application thereof | |
| CN116948901A (en) | Application of Weissella antrum D-2 extracellular polysaccharide in inhibiting colon cancer cells | |
| CN110881555A (en) | Dispersible candy tablet with dual-effect of lowering blood pressure | |
| CN110710675A (en) | Prebiotics polypeptide composite probiotics for treating gastrointestinal disorder and abdominal distension and diarrhea and preparation method thereof | |
| CN113521262A (en) | Lysozyme preparation with anti-inflammatory effect | |
| CN104490799B (en) | A kind of Phloroglucinol for injection lyophilised compositions and its preparation method | |
| CN106190756A (en) | Herba Spinaciae health promoting vinegar and application thereof | |
| CN110693008A (en) | Prebiotics polypeptide composite probiotics for treating constipation and dyspepsia and preparation method thereof | |
| CN1243443A (en) | Fresh rehmannia root extract for proliferation of bifidobactor and extraction method thereof | |
| CN111743961A (en) | Preparation method of pure fermented pinellia ternata koji | |
| CN115212225B (en) | Application of RS3 resistant starch in medicine for preventing and treating ischemic cerebral apoplexy and preparation thereof | |
| CN117298177B (en) | Natural immunomodulator and preparation method thereof | |
| CN112425784B (en) | Preparation method of functional food for balancing intestinal flora and intestinal immunity | |
| CN110051596B (en) | Antibacterial and anti-inflammatory dendrobium toothpaste | |
| CN114053390B (en) | Traditional Chinese medicine composition with hypoxia tolerance and preparation method and application thereof | |
| CN117618515A (en) | Traditional Chinese medicine probiotic composition for controlling weight and reducing hepatic steatosis | |
| CN111700145A (en) | Celery and sealwort enzyme tablet candy and application and preparation method thereof | |
| CN111450187A (en) | A Chinese medicinal composition for the comprehensive treatment of stomach diseases | |
| CN117562934A (en) | Application of pharmaceutical composition in preparation of medicine for preventing and/or treating type II diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210813 |